Last Price
2.00
Today's Change
+0.16 (8.69%)
Day's Change
1.79 - 2.08
Trading Volume
678,201
Market Cap
62 Million
Shares Outstanding
31 Million
Avg Volume
1,246,388
Avg Price (50 Days)
2.01
Avg Price (200 Days)
1.87
PE Ratio
-1.02
EPS
-1.97
Earnings Announcement
05-Mar-2025
Previous Close
1.84
Open
1.79
Day's Range
1.79 - 2.08
Year Range
1.0 - 7.92
Trading Volume
678,679
1 Day Change
8.70%
5 Day Change
22.70%
1 Month Change
-5.21%
3 Month Change
-37.69%
6 Month Change
39.86%
Ytd Change
-72.68%
1 Year Change
-71.35%
3 Year Change
-91.11%
5 Year Change
-88.63%
10 Year Change
-88.63%
Max Change
-88.63%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.